NHS Supply Chain Diagnostic and Capital Equipment Framework: Preparing for the 30 November 2026 Deadline

NHS Supply Chain Diagnostic and Capital Equipment Framework: Preparing for the 30 November 2026 Deadline

The NHS Supply Chain Diagnostic and Capital Equipment and Related Accessories and Services framework closes at 15:00 on 30 November 2026, giving medical device manufacturers and distributors five weeks from this week (week starting 2026-10-24) to prepare a response to one of the highest-value healthcare procurements currently live. This is a £4.33 billion framework running to April 2031 with seven lots covering diagnostic and capital equipment, and it demands detailed product evidence, clinical engagement records, and total cost of ownership modelling that most suppliers underestimate in both scope and time.

The framework notice, published as reference 091367-2026 on Find a Tender and accessible through the NHS Supply Chain Jaggaer portal under Project_2351, was issued on 6 October 2026. It operates as an open framework scheme with both transacted and direct routes of supply, which matters for how you position pricing and the degree of pass-through you build into your commercial model.

Choosing your lots and understanding the scheme structure

The seven lots divide diagnostic and capital equipment by clinical function and procurement route. You apply only to the lots where you hold current NHS approvals or can evidence live clinical deployment. The transacted route means NHS Supply Chain holds the stock and fulfils orders, which affects your margin structure and whether you can support just-in-time delivery without maintaining local inventory. The direct route allows you to supply named trusts under call-off, which gives you margin control but requires you to manage logistics and service-level agreements independently.

Most suppliers with imaging equipment or laboratory diagnostics apply to three or four lots. Applying to more dilutes your proposal quality unless you genuinely operate across clinical domains with separate technical teams. Evaluators score each lot separately and expect named clinical case studies per lot, not generic statements about capability.

The framework runs to April 2031, but call-off contracts will typically run two to four years depending on equipment lifecycle and trust capital planning cycles. This is critical for understanding the revenue model. You are not awarded a share of £4.33 billion when you join the framework. You win revenue only when trusts issue call-offs, and that depends on your pricing, clinical evidence, incumbent relationships, and post-sale support offer.

Product evidence and clinical engagement

Evaluators score product evidence by reviewing regulatory approvals, clinical trial data where relevant, and references from NHS trusts or equivalent health systems. A worked example: a diagnostic imaging supplier bidding for the relevant lot submits CE and UKCA marking, ISO 13485 certification, and three named references from NHS acute trusts where the equipment has been deployed for at least 12 months. The references must include contact details for clinical leads, not just procurement. One reference is scored at zero if the named contact does not respond to the evaluation team within the verification window.

Clinical engagement means showing how you work with radiologists, pathologists, or relevant clinicians during specification, installation, and optimisation. Evaluators look for formal clinical advisory arrangements, training programmes delivered on-site with attendance records, and evidence that clinicians influenced product configuration or accessories offered. A generic statement that you "engage closely with clinical teams" scores poorly. A named example of a clinical lead who co-designed a training module and can verify this on request scores well.

You also need to evidence conformance with NHS technical standards, including interoperability with existing PACS, LIMS, or EPR systems. If your equipment cannot integrate with the systems used by the majority of acute trusts, you will struggle to win call-offs even if you are awarded a place on the framework.

Service, maintenance, and total cost of ownership

The buyer is explicit that evaluation includes whole-life costs, not just capital purchase price. Your submission must model total cost of ownership over a realistic equipment lifecycle, typically five to ten years for capital items. This includes purchase price, installation and commissioning, annual service contracts, consumables, software upgrades, training, and decommissioning.

An illustrative example: a supplier of laboratory diagnostic equipment proposes a capital price of £180,000, annual service at £18,000, consumables at £12,000 per year based on projected throughput, and a software licence at £4,000 per year. Over seven years, total cost of ownership is £418,000. A competitor offers equipment at £220,000 capital but £10,000 annual service, £8,000 consumables, and no separate software fee, giving a total of £346,000 over the same period. The second offer is more competitive unless the first supplier can evidence significantly better clinical outcomes, uptime, or operational efficiency that justifies the premium.

Service-level agreements must specify response times, parts availability, and remote diagnostics capability. Many trusts now expect four-hour response for critical diagnostic equipment and same-day parts delivery from UK stock. If you rely on parts shipped from overseas or a single service engineer covering a region, this will limit your competitiveness on certain lots.

Maintenance proposals should also cover technology refresh cycles and backward compatibility. Trusts want assurance that software updates will not require hardware replacement within the expected life of the equipment, and that consumables will remain available even if you discontinue a product line.

Pricing models and framework mechanics

Pricing can be submitted as a fixed schedule, a discount matrix, or a cost-plus model depending on lot and supply route. For transacted supply, you typically quote a transfer price to NHS Supply Chain and they apply their margin. For direct supply, you quote end-user pricing but must demonstrate that it is competitive against other frameworks and spot procurement.

Some suppliers index pricing to published cost indices or agree annual review mechanisms. This is acceptable if clearly described and the methodology is transparent. Evaluators will compare your pricing against current spend data and benchmark it against the previous framework and other routes to market.

You also need to confirm whether your pricing includes delivery, installation, commissioning, initial training, and first-year maintenance, or whether these are priced separately. Trusts prefer inclusive pricing because it simplifies budget approvals, but disaggregated pricing can be more competitive if your installation and training costs are genuinely lower than competitors.

Social value and the 10 per cent weighting

Social value carries a 10 per cent evaluation weighting and is scored against the government's themes: COVID-19 recovery, tackling economic inequality, equal opportunity, and wellbeing. For medical device suppliers, the strongest responses focus on UK manufacturing or assembly, apprenticeships in clinical engineering or technical roles, and partnerships with NHS trusts on workforce development.

A measurable commitment works better than a general statement. For example, committing to employ two apprentices per year in your UK service operation and providing placement opportunities for biomedical engineering students is specific and verifiable. Offering to run free clinical training workshops for smaller trusts or community providers addresses inequality of access and can be evidenced through attendance records.

Avoid double-counting social value that is already priced into your commercial offer. If you employ UK-based service engineers, that is part of your service delivery model, not additional social value unless you are creating new roles or upskilling the workforce beyond normal business requirements.

Four-week timeline from this week

From this week (week starting 2026-10-24), you have four clear working weeks until the 15:00 deadline on 30 November 2026. Week one should focus on lot selection, gathering product certifications, and identifying clinical references. Week two is for drafting technical responses, building total cost of ownership models, and confirming pricing structures with finance. Week three is for writing service and maintenance proposals, social value commitments, and quality checks. Week four is for internal review, reference verification, and final submission through the Jaggaer portal.

Late-stage preparation compresses this timeline significantly. If you are starting in the final two weeks, you will need to prioritise the highest-scoring evaluation criteria and accept that some sections will be less detailed than optimal. Our late-stage bid support arrangements exist for exactly this scenario, but the fewer days available, the more constrained your options become.

Most suppliers underestimate the time required to gather clinical references and have them verified. Start this process immediately. If you wait until the final week and a referee is unavailable or unresponsive, you cannot substitute a new one without rewriting the case study.

Framework award versus call-off revenue

Being awarded a place on the framework in early 2027 does not generate revenue. Revenue comes from call-off contracts issued by individual trusts or through the transacted route managed by NHS Supply Chain. Trusts will run mini-competitions among framework suppliers or directly award to a single supplier based on price, clinical preference, or existing relationships.

This distinction matters for how you model return on investment for the bid. If you spend £30,000 preparing a submission and are awarded a place on the framework, you recover that cost only when you win call-offs. Some suppliers win three or four high-value call-offs in the first year and make the framework highly profitable. Others win a place but struggle to convert it into revenue because their pricing or service offer is not competitive in live procurements, or because they lack the relationships and account management resource to respond to mini-competitions quickly.

Our revenue model reflects this commercial reality. We charge a success fee tied to call-off contract wins, not to framework award. You can read more about how we work with healthcare suppliers in our NHS framework specialists overview.

Frequently asked questions

Can I apply to all seven lots to maximise my chances of winning call-offs?

You can apply to multiple lots, but only where you can evidence genuine capability and clinical deployment in each area. Evaluators score lots separately and expect specific product case studies, not generic capability statements. Applying to lots where your evidence is weak dilutes your overall quality and wastes evaluation resource on sections that will score poorly. Most competitive suppliers focus on two to four lots where they have strong references and current NHS approvals.

What happens if I win a framework place but my pricing is higher than other suppliers on the same lot?

You remain on the framework until April 2031 but will find it difficult to win call-offs unless you can evidence superior clinical outcomes, service levels, or total cost of ownership that justify the price premium. Trusts often run mini-competitions among framework suppliers and price is typically weighted at 30 to 40 per cent of the evaluation. If your capital price is 20 per cent higher than a competitor and your whole-life costs are similar, you need a significant quality advantage to win. Some suppliers use their framework place to build relationships and offer demonstration units or extended trials, then compete more aggressively on price for the formal call-off.

How quickly are framework awards typically announced after the November 2026 deadline?

For a procurement of this scale and value, evaluation typically takes three to four months, meaning awards would be announced around March or April 2027. Standstill periods and any legal challenges can extend this further. You should not assume revenue from this framework in your financial year ending March 2027. Plan for call-off opportunities to begin from mid-2027 onwards, and understand that building a pipeline of live opportunities takes a further three to six months depending on trust capital planning cycles and your account management activity.

Call 020 3668 5488

Glaxtons, 3 More London Place, London SE1 2RE